![A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment | Orphanet Journal of Rare Diseases A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment | Orphanet Journal of Rare Diseases](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13023-015-0293-y/MediaObjects/13023_2015_293_Fig1_HTML.gif)
A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment | Orphanet Journal of Rare Diseases
![Frontiers | Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A Frontiers | Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A](https://www.frontiersin.org/files/Articles/930435/fneur-13-930435-HTML/image_m/fneur-13-930435-g001.jpg)
Frontiers | Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT): A Protocol to Address Clinical Trial Readiness in CMT1A
![Level of mobility and overall neuropathy limitation score pretreatment... | Download Scientific Diagram Level of mobility and overall neuropathy limitation score pretreatment... | Download Scientific Diagram](https://www.researchgate.net/profile/Shirley-Dsa/publication/342597474/figure/fig1/AS:913468798554112@1594799341839/Level-of-mobility-and-overall-neuropathy-limitation-score-pretreatment-and-posttreatment_Q320.jpg)
Level of mobility and overall neuropathy limitation score pretreatment... | Download Scientific Diagram
![A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. - Abstract - Europe PMC A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. - Abstract - Europe PMC](https://europepmc.org/articles/PMC2077620/bin/jn81547.f1.jpg)
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. - Abstract - Europe PMC
![Sensory Examination Tool for Clinicians – Adult and pediatric printable resources for speech and occupational therapists Sensory Examination Tool for Clinicians – Adult and pediatric printable resources for speech and occupational therapists](https://therapyinsights.com/wp-content/uploads/2022/01/sensory-exam-tool-for-pt.jpg)
Sensory Examination Tool for Clinicians – Adult and pediatric printable resources for speech and occupational therapists
![Table 1 from Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies | Semantic Scholar Table 1 from Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0366335a8358f91d30d6e246593232880a67df74/3-Table1-1.png)
Table 1 from Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies | Semantic Scholar
![Table 4 from Residual disability 10years after falling ill in Guillain–Barré syndrome: A prospective follow-up study | Semantic Scholar Table 4 from Residual disability 10years after falling ill in Guillain–Barré syndrome: A prospective follow-up study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/58bb6f540ab2a1323151d07b58e3467be4bf22f6/5-Table4-1.png)
Table 4 from Residual disability 10years after falling ill in Guillain–Barré syndrome: A prospective follow-up study | Semantic Scholar
![Figure 2 from Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies | Semantic Scholar Figure 2 from Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0366335a8358f91d30d6e246593232880a67df74/6-Figure2-1.png)
Figure 2 from Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies | Semantic Scholar
![Trial design and outcomes for inherited neuropathy studies D. Pareyson IRCCS Foundation C.Besta Neurological Institute Milan, Italy MSG Meeting, Buffalo, - ppt download Trial design and outcomes for inherited neuropathy studies D. Pareyson IRCCS Foundation C.Besta Neurological Institute Milan, Italy MSG Meeting, Buffalo, - ppt download](https://images.slideplayer.com/16/4913876/slides/slide_20.jpg)
Trial design and outcomes for inherited neuropathy studies D. Pareyson IRCCS Foundation C.Besta Neurological Institute Milan, Italy MSG Meeting, Buffalo, - ppt download
![Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy | Neurology and Therapy Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy | Neurology and Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40120-019-0132-5/MediaObjects/40120_2019_132_Fig1_HTML.png)
Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy | Neurology and Therapy
![Clinimetric properties of a walking scale in peripheral neuropathy | Journal of Neurology, Neurosurgery & Psychiatry Clinimetric properties of a walking scale in peripheral neuropathy | Journal of Neurology, Neurosurgery & Psychiatry](https://jnnp.bmj.com/content/jnnp/77/8/977/F1.large.jpg)
Clinimetric properties of a walking scale in peripheral neuropathy | Journal of Neurology, Neurosurgery & Psychiatry
![Medicina | Free Full-Text | Peripheral Nerve Ultrasound for the Differentiation between ALS, Inflammatory, and Hereditary Polyneuropathies Medicina | Free Full-Text | Peripheral Nerve Ultrasound for the Differentiation between ALS, Inflammatory, and Hereditary Polyneuropathies](https://www.mdpi.com/medicina/medicina-59-01192/article_deploy/html/images/medicina-59-01192-g001-550.jpg)